JP2020536085A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536085A5
JP2020536085A5 JP2020518682A JP2020518682A JP2020536085A5 JP 2020536085 A5 JP2020536085 A5 JP 2020536085A5 JP 2020518682 A JP2020518682 A JP 2020518682A JP 2020518682 A JP2020518682 A JP 2020518682A JP 2020536085 A5 JP2020536085 A5 JP 2020536085A5
Authority
JP
Japan
Prior art keywords
treatment
combination according
tuberculosis
medicament
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020518682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536085A (ja
JP7233059B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/077222 external-priority patent/WO2019068910A1/en
Publication of JP2020536085A publication Critical patent/JP2020536085A/ja
Publication of JP2020536085A5 publication Critical patent/JP2020536085A5/ja
Application granted granted Critical
Publication of JP7233059B2 publication Critical patent/JP7233059B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020518682A 2017-10-05 2018-10-05 結核に対する薬剤と組み合わせた環融合型チアゾリノ２－ピリドン Active JP7233059B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568430P 2017-10-05 2017-10-05
US62/568,430 2017-10-05
US201862716054P 2018-08-08 2018-08-08
US62/716,054 2018-08-08
PCT/EP2018/077222 WO2019068910A1 (en) 2017-10-05 2018-10-05 THIAZOLINO 2-PYRIDONES WITH A FUSED CYCLE IN COMBINATION WITH A MEDICINE AGAINST TUBERCULOSIS

Publications (3)

Publication Number Publication Date
JP2020536085A JP2020536085A (ja) 2020-12-10
JP2020536085A5 true JP2020536085A5 (enExample) 2021-11-11
JP7233059B2 JP7233059B2 (ja) 2023-03-06

Family

ID=63840820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020518682A Active JP7233059B2 (ja) 2017-10-05 2018-10-05 結核に対する薬剤と組み合わせた環融合型チアゾリノ２－ピリドン

Country Status (7)

Country Link
US (1) US11129816B2 (enExample)
EP (1) EP3691619A1 (enExample)
JP (1) JP7233059B2 (enExample)
KR (1) KR20200066315A (enExample)
CN (1) CN111246848A (enExample)
PH (1) PH12020550567A1 (enExample)
WO (1) WO2019068910A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799513B (zh) * 2017-06-13 2023-04-14 快尔生物技术公司 环稠合噻唑并-2-吡啶酮、其制备方法及其治疗和/或预防涉及革兰氏阳性菌的疾病的应用
US12410165B2 (en) * 2019-07-30 2025-09-09 Qurient Co., Ltd. Different forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
PL4146659T3 (pl) * 2020-05-08 2025-06-23 Quretech Bio Ab Pierścieniowo skondensowane związki 2-pirydonowe, sposoby ich wytwarzania i ich zastosowanie w leczeniu i/lub zapobieganiu chorobie z udziałem bakterii gram-dodatnich
CN112921107A (zh) * 2020-12-31 2021-06-08 深圳市慢性病防治中心(深圳市皮肤病防治研究所、深圳市肺部疾病防治研究所) 结核分枝杆菌异质性耐药检测方法、试剂盒及应用
CN113045494B (zh) * 2021-03-29 2022-04-26 四川大学华西医院 吡啶酮衍生物及其在制备预防和/或治疗结核分枝杆菌所引起的结核病的药物中的用途
CN115531388B (zh) * 2022-11-04 2024-03-22 首都医科大学附属北京胸科医院 治疗结核病的药物组合物
CN118593520B (zh) * 2024-05-23 2025-01-24 蚌埠医科大学 化合物k67在制备抗结核药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
EP3974975B1 (en) 2013-05-13 2023-04-05 Telefonaktiebolaget LM Ericsson (publ) Node in a telecommunications network, a virtual network element and methods for retrieving resource identification information
WO2014185853A1 (en) 2013-05-14 2014-11-20 Quretech Bio Ab Compounds and methods for treatment of chlamydia infections
WO2015011163A1 (en) * 2013-07-26 2015-01-29 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
CN105745208A (zh) 2013-08-02 2016-07-06 韩国巴斯德研究所 一种抗感染化合物
US10294244B2 (en) 2014-11-13 2019-05-21 Quretech Bio Ab 2,3-dihydro-thiazolo[3,2-A]pyridin-5-one derivatives, intermediates thereof, and their use as antibacterial agents
CN109069492B (zh) * 2016-04-08 2021-12-10 快尔生物技术公司 环稠和的噻唑啉2-吡啶酮、其制备方法及其在治疗和/或预防结核中的用途

Similar Documents

Publication Publication Date Title
JP2020536085A5 (enExample)
EP4596041A3 (en) Farnesoid x receptor agonists and uses thereof
JP2015057451A5 (enExample)
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
JP2016515522A5 (enExample)
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
JP2017537928A5 (enExample)
WO2018004283A3 (ko) 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
WO2015077503A8 (en) Autotaxin inhibitor compounds
JP2016147915A5 (enExample)
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
JP2018202656A5 (enExample)
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP4324824A3 (en) Combination antibacterial composition and short-course antibacterial regimen
CN110035744A (zh) 一种尼拉帕尼缓控释药物组合物及其用途
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
EP3318282A4 (en) AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
JP2016540030A5 (enExample)
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
CA3010981A1 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
HUE055732T2 (hu) Új tetrazolvegyületek és felhasználásuk a tuberkulózis kezelésében
JP2017197541A5 (enExample)